Replimune is a biotech developing cancer-killing viruses (oncolytic immuno-gene therapies) that infect tumor cells and trigger the immune system to attack them. Its lead drug, RP1, is in Phase I/II trials for solid tumors and Phase II for a skin cancer.
The company has no revenue and is burning cash: operating losses were USD -0.32B in fiscal 2026, -0.26B in 2025, and -0.23B in 2024. Quarterly losses have ranged from USD -0.07B to -0.09B, so it relies entirely on funding, not sales.
Its platform is early-stage and unproven, with no approved products. Competitors like Amgen and Merck are far ahead in cancer immunotherapy, and any clinical failure could erase its value. The moat is weak because the science is speculative and easily challeng
Key events, in time order
FDA grants accelerated approval for TUDRIQEV+nivolumab in anti-PD-1 refractory unresectable melanoma; launch expected within 60 days
Q1 net loss $69.8M; $150M financing closed; FDA-approved therapy launches within 60 days
Two firms alert investors; suits relate to disclosure issues
None yet
None yet
Replimune is identified as a stock exhibiting strong relative strength within a tight price range, suggesting potential for a breakout. The discussion focuses on technical indicators and momentum.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
